Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells

AIM: The mammalian target of rapamycin (mTOR) pathway is a critical target for cancer treatment and the mTOR inhibitor everolimus (RAD001) has been approved for treatment of renal cell carcinoma (RCC). However, the limited efficacy of RAD001 has led to the development of drug resistance. Autophagy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Yizhou, Tian, Xiaofang, Wang, Quan, He, Weiyang, Fan, Jing, Gou, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914548/
https://www.ncbi.nlm.nih.gov/pubmed/29719377
http://dx.doi.org/10.2147/DDDT.S160557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914548/
https://www.ncbi.nlm.nih.gov/pubmed/29719377
http://dx.doi.org/10.2147/DDDT.S160557

Ejemplares similares